Zhejiang Shouxiangu Pharm Co (SHG:603896) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Shouxiangu Pharm Co (603896)
Zhejiang Shouxiangu Pharm Co (SHG:603896) has a market capitalization of $409.32 Million (CN¥2.80 Billion) as of September 21, 2026. Listed on the SHG stock exchange, this China-based company holds position #13407 globally and #4006 in its home market, demonstrating a -4.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Shouxiangu Pharm Co's stock price CN¥14.11 by its total outstanding shares 198243938 (198.24 Million). Also see 603896 asset base for a full breakdown of the balance sheet.
Zhejiang Shouxiangu Pharm Co Market Cap History: 2017 to 2026
Zhejiang Shouxiangu Pharm Co's market capitalization history from 2017 to 2026. Data shows growth from $1.21 Billion to $409.32 Million (1.64% CAGR). Also see 603896 operating cash flow for how efficiently the company converts equity into cash flow.
Zhejiang Shouxiangu Pharm Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Shouxiangu Pharm Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Zhejiang Shouxiangu Pharm Co share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.88x
Zhejiang Shouxiangu Pharm Co's market cap is 0.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
30.93x
Zhejiang Shouxiangu Pharm Co's market cap is 30.93 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.21 Billion | $369.96 Million | $88.88 Million | 3.26x | 13.59x |
| 2018 | $562.22 Million | $511.45 Million | $107.65 Million | 1.10x | 5.22x |
| 2019 | $646.10 Million | $546.76 Million | $123.90 Million | 1.18x | 5.21x |
| 2020 | $761.19 Million | $636.05 Million | $151.71 Million | 1.20x | 5.02x |
| 2021 | $1.27 Billion | $767.14 Million | $200.83 Million | 1.65x | 6.31x |
| 2022 | $1.14 Billion | $829.07 Million | $277.78 Million | 1.37x | 4.10x |
| 2023 | $935.26 Million | $784.35 Million | $254.48 Million | 1.19x | 3.68x |
| 2024 | $615.29 Million | $691.68 Million | $174.71 Million | 0.89x | 3.52x |
| 2025 | $562.20 Million | $640.18 Million | $18.17 Million | 0.88x | 30.93x |
Competitor Companies of 603896 by Market Capitalization
Companies near Zhejiang Shouxiangu Pharm Co in the global market cap rankings as of September 21, 2026. Review 603896 tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Zhejiang Shouxiangu Pharm Co by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Zhejiang Shouxiangu Pharm Co Historical Marketcap From 2017 to 2026
Between 2017 and today, Zhejiang Shouxiangu Pharm Co's market cap moved from $1.21 Billion to $ 409.32 Million, with a yearly change of 1.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥409.32 Million | -27.19% |
| 2025 | CN¥562.20 Million | -8.63% |
| 2024 | CN¥615.29 Million | -34.21% |
| 2023 | CN¥935.26 Million | -17.86% |
| 2022 | CN¥1.14 Billion | -10.15% |
| 2021 | CN¥1.27 Billion | +66.47% |
| 2020 | CN¥761.19 Million | +17.81% |
| 2019 | CN¥646.10 Million | +14.92% |
| 2018 | CN¥562.22 Million | -53.44% |
| 2017 | CN¥1.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Zhejiang Shouxiangu Pharm Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $409.32 Million USD |
| MoneyControl | $409.32 Million USD |
| MarketWatch | $409.32 Million USD |
| marketcap.company | $409.32 Million USD |
| Reuters | $409.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Shouxiangu Pharm Co
Zhejiang Shouxiangu Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the breeding, cultivation, processing, and sale of Chinese medicinal herbs in China and internationally. The company offers ganoderma lucidum spore powder, dendrobium officinale, and saffron products, as well as health and ordinary food, agricultural and sideline products, personal and skincare, and tradition… Read more